Scholarlink

Purpose <p>Individuals who have completed colorectal cancer (CRC) treatment are recommended regular radiological scans for 3–5&#xa0;years to monitor for cancer recurrence. Since the frequency of radiological surveillance is generally reduced until it is no longer recommended, blood tests measuring circulating tumor DNA (ctDNA) could supplement and/or replace radiological surveillance once scans are not recommended. To better understand patients’ support needs throughout ongoing care after CRC treatment, this study explored perspectives on reduced scan frequency and the potential incorporation of ctDNA tests.</p> Methods <p>Eight focus groups were conducted with 21 individuals (11 males; median age at diagnosis 61&#xa0;years) who received CRC treatment in South Australia. Reflexive thematic analysis was used to develop and interpret themes.</p> Results <p>Participants' reported mental wellbeing was linked to their perceived health status following CRC treatment, and radiological surveillance was important in forming these perceptions. Perspectives on reduced surveillance frequency differed by participants’ level of health anxiety. Although some individuals interpreted surveillance changes as a positive indicator of their ongoing cancer-free health, others felt this would lead to more uncertainty regarding their cancer status. Participants supported the incorporation of ctDNA blood tests to provide additional information about their risk of recurrence.</p> Conclusion <p>Individuals lacking information about their cancer status may have a higher risk of experiencing adverse mental health outcomes (e.g., fear of cancer recurrence) following reductions in surveillance frequency. Using ctDNA tests may help decrease fears of recurrence and support perceptions of good health during times of radiological surveillance change.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

“A lot can happen in that time”: understanding patients’ perspectives on reduced surveillance frequency and the potential for circulating tumor DNA blood tests after colorectal cancer treatment

  • 期刊论文

  • 发表日期：

    2025年11月19日

查看全文
  • Maddison Dix,
  • Donna Hughes-Barton,
  • Renee J. Smith,
  • Emma Kemp,
  • Sarah Cohen-Woods,
  • Jean M. Winter,
  • Timothy J. H. Lathlean,
  • Carlene J. Wilson,
  • Graeme P. Young,
  • Charles Cock,
  • Erin L. Symonds

摘要

Purpose

Individuals who have completed colorectal cancer (CRC) treatment are recommended regular radiological scans for 3–5 years to monitor for cancer recurrence. Since the frequency of radiological surveillance is generally reduced until it is no longer recommended, blood tests measuring circulating tumor DNA (ctDNA) could supplement and/or replace radiological surveillance once scans are not recommended. To better understand patients’ support needs throughout ongoing care after CRC treatment, this study explored perspectives on reduced scan frequency and the potential incorporation of ctDNA tests.

Methods

Eight focus groups were conducted with 21 individuals (11 males; median age at diagnosis 61 years) who received CRC treatment in South Australia. Reflexive thematic analysis was used to develop and interpret themes.

Results

Participants' reported mental wellbeing was linked to their perceived health status following CRC treatment, and radiological surveillance was important in forming these perceptions. Perspectives on reduced surveillance frequency differed by participants’ level of health anxiety. Although some individuals interpreted surveillance changes as a positive indicator of their ongoing cancer-free health, others felt this would lead to more uncertainty regarding their cancer status. Participants supported the incorporation of ctDNA blood tests to provide additional information about their risk of recurrence.

Conclusion

Individuals lacking information about their cancer status may have a higher risk of experiencing adverse mental health outcomes (e.g., fear of cancer recurrence) following reductions in surveillance frequency. Using ctDNA tests may help decrease fears of recurrence and support perceptions of good health during times of radiological surveillance change.